Key Dates

Related Announcements

• November 04, 2024 – “NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)”. See NOFO PAR-25-139.

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to change the due date, expiration date, and allowed resubmission NOFOs specified in the Award Information, Application Types Allowed in Section II and one of the scientific contacts in Section VII of the PAR-25-139.

Part 1 Overview Information

Key Dates

Currently, Reads:

Expiration Date: July 02, 2025

Modified to Read (in bold italics):

Expiration Date: September 08, 2025

Section II. Award Information

Application Types Allowed

Currently, Reads:

New
Resubmission - Resubmission of applications to PAR-19-356, PAR-20-292 and this NOFO.

Modified to Read (in bold italics):

New

Resubmission - Resubmission of applications to PAR-19-356, PAR-20-292, PAR-22-216 and this NOFO.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Currently, Reads:

Applications Related to Cancer Treatment/Diagnosis (Clinical Studies):

Anita Undale, MD, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5251
Email: [email protected]

Modified to Read (in bold italics):

Applications Related to Cancer Treatment/Diagnosis (Clinical Studies):
Minkyung (Min) Song, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6139
Email: [email protected]
 

All other aspects of the PAR-25-139 remain unchanged.

Inquiries

Please direct all inquiries to:

Morgan O’Hayre, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7482
Email: [email protected]